This research assessed the sub-chronic toxicity (90-day) and anti-ulcer efficacy of the
hydroethanolic leaf extract of Vernonia amygdalina in rodent models. For toxicity
testing, Wistar rats were given daily doses of 0, 250, 500, or 1000 mg/kg for 90 days.
There were no deaths at any dose. The No Observed Adverse Effect Level (NOAEL)
was set at 500 mg/kg. At 1000 mg/kg, there were small increases in serum liver
enzymes (ALT, AST, ALP), creatinine, and blood urea nitrogen. Histopathology
showed mild hepatocellular necrosis and renal tubular degeneration. For the
assessment of anti-ulcer efficacy, Swiss albino mice were administered the extract
(100–400 mg/kg) or omeprazole (20 mg/kg) for seven days prior to ulcer induction via
ethanol, indomethacin, or pylorus ligation models. The extract at 400 mg/kg showed
strong gastroprotection, with 86.3% protection against ulcers caused by ethanol (p <
0.001), 74.2% protection against ulcers caused by indomethacin (p < 0.01), and
antisecretory effects that included a 58.4% reduction in gastric juice volume and an
increase in gastric pH from 2.1 to 4.2 in the pylorus ligation model. These effects were
similar to those of omeprazole. Phytochemical analysis showed that the contents of
phenolic (124.5 mg/g) and flavonoid (67.8 mg/g) were very high. The results confirm
the historical application of Vernonia amygdalina for gastric ailments and
demonstrate a positive safety profile after multiple doses. The extract demonstrates
multi-mechanistic anti-ulcer activity through antioxidant, cytoprotective, and
antisecretory mechanisms. Additional mechanistic investigations and clinical trials
are necessary.
Keywords: Vernonia amygdalina; anti-ulcer efficacy; sub-chronic toxicity; gastric
ulcer; rodent models; phytomedicine; NOAEL
